Stephen M. Ansell

51.7k total citations · 5 hit papers
741 papers, 26.6k citations indexed

About

Stephen M. Ansell is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Stephen M. Ansell has authored 741 papers receiving a total of 26.6k indexed citations (citations by other indexed papers that have themselves been cited), including 524 papers in Pathology and Forensic Medicine, 364 papers in Oncology and 254 papers in Genetics. Recurrent topics in Stephen M. Ansell's work include Lymphoma Diagnosis and Treatment (517 papers), Chronic Lymphocytic Leukemia Research (242 papers) and CAR-T cell therapy research (137 papers). Stephen M. Ansell is often cited by papers focused on Lymphoma Diagnosis and Treatment (517 papers), Chronic Lymphocytic Leukemia Research (242 papers) and CAR-T cell therapy research (137 papers). Stephen M. Ansell collaborates with scholars based in United States, Canada and United Kingdom. Stephen M. Ansell's co-authors include Thomas E. Witzig, Anne J. Novak, Thomas M. Habermann, David J. Inwards, Ivana N. Micallef, Zhi‐Zhang Yang, Steven C. Ziesmer, Luis F. Porrata, Philippe Armand and John M. Timmerman and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Stephen M. Ansell

707 papers receiving 26.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

2014 2.7k citations Stephen M. Ansell, John M. Timmerman et al. profile →
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

2012 1.0k citations Anas Younes, Ajay K. Gopal et al. Journal of Clinical Oncology profile →
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

2019 594 citations Yucai Wang, Grzegorz S. Nowakowski et al. profile →
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

2018 455 citations Philippe Armand, Andreas Engert et al. Journal of Clinical Oncology profile →
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy

2016 305 citations Bruce D. Cheson, Stephen M. Ansell et al. Blood profile →

Peers

Countries citing papers authored by Stephen M. Ansell

Since Specialization

Citations

This map shows the geographic impact of Stephen M. Ansell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen M. Ansell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen M. Ansell more than expected).

Fields of papers citing papers by Stephen M. Ansell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen M. Ansell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen M. Ansell. The network helps show where Stephen M. Ansell may publish in the future.

Co-authorship network of co-authors of Stephen M. Ansell

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen M. Ansell. A scholar is included among the top collaborators of Stephen M. Ansell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen M. Ansell. Stephen M. Ansell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy 2024 ·Haematologica ·Aung M. Tun, Yucai Wang, Seth Maliske, Ivana N. Micallef, David J. Inwards, Thomas M. Habermann, Luis F. Porrata, Jonas Paludo, José C. Villasboas, Allison Rosenthal, Mohamed A. Kharfan‐Dabaja, Stephen M. Ansell, Grzegorz S. Nowakowski, Umar Farooq, Patrick B. Johnston	4
2	Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies 2023 ·Frontiers in Cell and Developmental Biology ·Vaishali Bhardwaj, Stephen M. Ansell	15
3	Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma 2022 ·Clinical Cancer Research ·Xinyi Tang, Zhi-Zhang Yang, Hyo Jin Kim, Theodora Anagnostou, Yue Yu, Xiaosheng Wu, Jun Chen, Jordan E. Krull, Kerstin Wenzl, Patrizia Mondello, Vaishali Bhardwaj, Junwen Wang, Anne J. Novak, Stephen M. Ansell	4
4	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia 2021 ·Blood Cancer Discovery ·Akhilesh Kaushal, Ajay K. Nooka, (unknown), Katherine E. Pendleton, Benjamin G. Barwick, (unknown), Samuel S. McCachren, Vikas A. Gupta, Nisha S. Joseph, Craig C. Hofmeister, Jonathan L. Kaufman, Leonard T. Heffner, Stephen M. Ansell, Lawrence Boise, Sagar Lonial, Kavita M. Dhodapkar, Madhav V. Dhodapkar	14
5	Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma 2020 ·Blood ·Alex F. Herrera, Carmelo Carlo‐Stella, Graham P. Collins, Kami J. Maddocks, Nancy L. Bartlett, Kerry J. Savage, Paolo F. Caimi, Brian Hess, Pier Luigi Zinzani, Hans G. Cruz, Luqiang Wang, Jay Feingold, Jens Wuerthner, Stephen M. Ansell	14
6	TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti–PD-1 Response in Follicular Lymphoma 2020 ·Clinical Cancer Research ·Zhi‐Zhang Yang, Hyo Jin Kim, Hongyan Wu, Shahrzad Jalali, Xinyi Tang, Jordan E. Krull, Wei Ding, Anne J. Novak, Stephen M. Ansell	82
7	Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells 2020 ·Clinical Cancer Research ·(unknown), (unknown), Rondell P. Graham, Nathan W. Cummins, (unknown), Enrique Garcia-Rivera, J. Anderson, Sekar Natesampillai, (unknown), (unknown), Zilin Nie, Thomas D.Y. Chung, Richard Buick, Andrew L. Feldman, Rebecca L. King, Anne J. Novak, Stephen M. Ansell, Saad S. Kenderian, Andrew D. Badley	5
8	A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408 2020 ·Clinical Cancer Research ·Andrew M. Evens, Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig, Andrew Quon, Erik A. Ranheim, Stephen M. Ansell, P. Cheema, (unknown), Timothy E. O’Brien, Jane N. Winter, Terrence P. Cescon, Julie Chang, Brad S. Kahl	16
9	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma 2019 ·Clinical Cancer Research ·Radhakrishnan Ramchandren, Ranjana H. Advani, Stephen M. Ansell, Nancy L. Bartlett, Robert Chen, Joseph M. Connors, Tatyana Feldman, Andres Forero‐Torres, Jonathan W. Friedberg, Ajay K. Gopal, Leo I. Gordon, John Kuruvilla, Kerry J. Savage, Anas Younes, (unknown), Thomas Manley, Keenan Fenton, David J. Straus	30
10	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial breakdown → 2018 ·Journal of Clinical Oncology ·Philippe Armand, Andreas Engert, Anas Younes, Michelle A. Fanale, Armando Santoro, Pier Luigi Zinzani, John M. Timmerman, Graham P. Collins, Radhakrishnan Ramchandren, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Margaret A. Shipp, Kazunobu Kato, Anne Sumbul, Benedetto Farsaci, Stephen M. Ansell	455
11	Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma 2017 ·Blood ·Alex F. Herrera, Alison J. Moskowitz, Nancy L. Bartlett, Julie M. Vose, Radhakrishnan Ramchandren, Tatyana Feldman, Ann S. LaCasce, Stephen M. Ansell, Craig H. Moskowitz, Keenan Fenton, Carol Anne Ogden, David R. Taft, Qu Zhang, Kazunobu Kato, Mary S. Campbell, Ranjana H. Advani	230
12	A phase II study of cyclophosphamide, etoposide, vincristine and prednisone ( CEOP ) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma ( PTCL ): final results from the T‐ cell consortium trial 2015 ·British Journal of Haematology ·Ranjana H. Advani, Stephen M. Ansell, Mary Jo Lechowicz, Anne Beaven, Fausto R. Loberiza, Kenneth R. Carson, Andrew M. Evens, Francine M. Foss, Steven M. Horwitz, Barbara Pro, Lauren Pinter‐Brown, Sonali M. Smith, Andrei R. Shustov, Kerry J. Savage, Julie M. Vose	66
13	Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia 2015 ·Clinical Cancer Research ·Isere Kuiatse, Veerabhadran Baladandayuthapani, Heather Lin, Sheeba K. Thomas, Chad C. Bjorklund, Donna M. Weber, Michael Wang, Jatin J. Shah, Xing‐Ding Zhang, Richard J. Jones, Stephen M. Ansell, Guang Yang, Steven P. Treon, Robert Z. Orlowski	16
14	Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy 2014 ·Blood ·Ann S. LaCasce, R. Gregory Bociek, Jeffrey Matous, Ahmed Sawas, Paolo Caimi, Stephen M. Ansell, Miguel Islas‐Ohlmayer, Eric Cheung, Edward Agura, Caroline Behler, Howland E. Crosswell, Julie M. Vose, Neil C. Josephson, Ranjana H. Advani	20
15	Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma breakdown → 2012 ·Journal of Clinical Oncology ·Anas Younes, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt, Kerry J. Savage, Radhakrishnan Ramchandren, Nancy L. Bartlett, Bruce D. Cheson, Sven de Vos, Andres Forero‐Torres, Craig H. Moskowitz, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Dana A. Kennedy, Eric L. Sievers, Robert Chen	1014
16	Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia 2010 ·Journal of Clinical Oncology ·Irene M. Ghobrial, Morie A. Gertz, Betsy LaPlant, John Camoriano, Suzanne R. Hayman, Martha Q. Lacy, Stacey Chuma, Brianna Harris, Renee Leduc, Meghan Rourke, Stephen M. Ansell, Daniel J. DeAngelo, Angela Dispenzieri, Leif Bergsagel, Craig B. Reeder, Kenneth C. Anderson, Paul G. Richardson, Steven P. Treon, Thomas E. Witzig	102
17	Germline Variation in Apoptosis Pathway Genes and Risk of Non–Hodgkin's Lymphoma 2010 ·Cancer Epidemiology Biomarkers & Prevention ·Jennifer L. Kelly, Anne J. Novak, Zachary S. Fredericksen, Mark Liebow, Stephen M. Ansell, Ahmet Doǧan, Alice H. Wang, Thomas E. Witzig, Timothy G. Call, Neil E. Kay, Thomas M. Habermann, Susan L. Slager, James R. Cerhan	34
18	Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma 2009 ·Clinical Cancer Research ·Stephen M. Ansell, Sara A. Hurvitz, Patricia Koenig, Betsy LaPlant, Brian Kabat, (unknown), Thomas M. Habermann, David J. Inwards, Meena Verma, Reiko Yamada, Charles Erlichman, Israel Lowy, John M. Timmerman	263
19	Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era 2009 ·Journal of Clinical Oncology ·Grzegorz S. Nowakowski, Matthew J. Maurer, Thomas M. Habermann, Stephen M. Ansell, William R. Macon, Kay M. Ristow, Cristine Allmer, Susan L. Slager, Thomas E. Witzig, James R. Cerhan	45
20	Malignant B Cells Skew the Balance of Regulatory T Cells and TH17 Cells in B-Cell Non-Hodgkin's Lymphoma 2009 ·Cancer Research ·Zhi‐Zhang Yang, Anne J. Novak, Steven C. Ziesmer, Thomas E. Witzig, Stephen M. Ansell	131

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact